<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157128</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-RET-17001 /J2G-OX-JZJA</org_study_id>
    <secondary_id>2017-000800-59</secondary_id>
    <nct_id>NCT03157128</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer</brief_title>
  <acronym>LIBRETTO-001</acronym>
  <official_title>A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Loxo Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety,
      tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib
      (also known as LOXO-292) administered orally to patients with advanced solid tumors,
      including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors
      with RET activation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center Phase 1/2 study in patients with advanced solid tumors,
      including RET fusion-positive solid tumors, MTC, and other tumors with RET activation. The
      trial will be conducted in 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion).
      Patients with advanced cancer are eligible if they have progressed on or are intolerant to
      available standard therapies, or no standard or available curative therapy exists, or in the
      opinion of the Investigator, they would be unlikely to tolerate or derive significant
      clinical benefit from appropriate standard of care therapy, or they declined standard
      therapy. A dose of 160 mg BID has been selected as the recommended phase 2 dose (RP2D). Up to
      ~850 patients with advanced solid tumors harboring a RET gene alteration in tumor and/or
      blood will be enrolled to one of five phase 2 cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Maximum tolerated dose (MTD)</measure>
    <time_frame>The first 28 days of treatment (Cycle 1)</time_frame>
    <description>Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>The first 28 days of treatment (Cycle 1) and every cycle (28 days) for approximately 12 months (or earlier if the patient discontinues from the study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective Response Rate</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
    <description>As assessed by RECIST v1.1 or RANO, as appropriate to tumor type, as assessed by independent review committee (IRC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Frequency, severity, and relatedness of TEAEs and serious adverse events (SAEs), changes in hematology and blood chemistry values, assessments of physical examinations, vital signs, and electrocardiograms (ECGs).</measure>
    <time_frame>From the time of informed consent, for approximately 24 months (or earlier if the patient discontinues from the study), and through Safety Follow-up (28 days after the last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Plasma concn of LOXO-292 (selpercatinib) and PK parameters, including but not limited to area under the curve from time 0 to 24 hrs (AUC0-24), max drug concn (Cmax), time to max plasma concn (Tmax), and degree of accumulation</measure>
    <time_frame>Day 8 of Cycle 1 and Day 8 after Intra-patient Dose Escalation (Phase 1 only)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: ORR based on RECIST 1.1 or RANO, as appropriate to tumor type.</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: ORR (by Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: best change in tumor size from baseline (by IRC and Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: DOR (by IRC and Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: CNS ORR (by IRC)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: CNS DOR (by IRC)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: time to any and best response (by IRC and Investigator)</measure>
    <time_frame>every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: CBR (by IRC and Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: PFS (by IRC and Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: OS</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Frequency, severity and relatedness of TEAEs and SAEs, changes in hematology and blood chemistry values, assessments of physical examinations, vital signs and ECGs.</measure>
    <time_frame>From the time of informed consent, for approximately 24 months (or earlier if the patient discontinues from the study), and through Safety Follow-up (28 days after the last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Plasma concentrations of LOXO-292 (selpercatinib) and PK parameters, including but not limited to AUC0-24, Cmax, and Tmax.</measure>
    <time_frame>Day 8 of Cycle 1 and Day 8 after Intra-patient Dose Escalation (Phase 2 only)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Differences in efficacy and safety based on LOXO-292 (selpercatinib) PK parameters.</measure>
    <time_frame>Day 8 of Cycle 1 and Day 8 after Intra-patient Dose Escalation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in CEA and calcitonin (patients with MTC) thyroglobulin (non-MTC thyroid cancer patients), ACTH and cortisol (patients with Cushing's disease related to their cancer) with LOXO-292 (selpercatinib) treatment.</measure>
    <time_frame>From the time of informed consent, Day 1 and Day 15 of Cycle 1, then with each radiologic disease assessment, and 7 days after the last dose.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Identity of RET gene fusions, mutations, and concurrently activated oncogenic pathways in tumor biopsies and cfDNA.</measure>
    <time_frame>Up to 28 days prior to C1D1, Day 1 &amp; Day 15 of Cycle 1, Day 1 of Cycle 3, then approximately every 8 weeks for 1 year, then every 12 weeks, &amp; 7 days after the last dose, for approximately 24 months (or earlier if the patient discontinues from the study)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in disease-related symptoms and HRQoL, as measured by EORTC QLQ-C30 (adults), PedsQL for teens (ages 13-17 years), and PedsQL for children (age 12 years).</measure>
    <time_frame>Day 1 of Cycle 1, then approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose, for approximately 24 months (or earlier if the patient discontinues from the study)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in disease-related symptoms and HRQoL, as measured by patient bowel diaries (MTC patients only).</measure>
    <time_frame>Day 1, Day 8, Day 15, and Day 22 of Cycle 1, and Day 1 of each cycle, and 7 days after the last dose, for approximately 24 months (or earlier if the patient discontinues from the study)</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">970</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Medullary Thyroid Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Any Solid Tumor</condition>
  <arm_group>
    <arm_group_label>LOXO-292 (Selpercatinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 - Multiple doses of LOXO-292 (selpercatinib) Phase 2 - The maximum tolerated dose (MTD)/recommended dose for Phase 2 (RP2D)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-292 (selpercatinib)</intervention_name>
    <description>Oral LOXO-292 (selpercatinib)</description>
    <arm_group_label>LOXO-292 (Selpercatinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        For Phase 1

          -  Patients with a locally advanced or metastatic solid tumor who:

               -  have progressed on or are intolerant to standard therapy, or

               -  no standard therapy exists, or in the opinion of the Investigator, are not
                  candidates for or would be unlikely to tolerate or derive significant clinical
                  benefit from standard therapy, or

               -  decline standard therapy

          -  Prior MKIs with anti-RET activity are allowed.

          -  A RET gene alteration is not required initially. Once adequate PK exposure is
             achieved, evidence of RET gene alteration in tumor and/or blood is required as
             identified through molecular assays, as performed for clinical evaluation.

          -  Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as
             appropriate to tumor type.

          -  Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 or Lansky Performance
             Score (LPS) ≥ 40% (age &lt; 16 years) with no sudden deterioration 2 weeks prior to the
             first dose of study treatment.

          -  Adequate hematologic, hepatic and renal function.

          -  Life expectancy of at least 3 months.

        For Phase 2

        As for phase 1 with the following modifications:

        - For Cohort 1 (up to 250 patients): Subjects must have received prior standard therapy
        appropriate for their tumor type and stage of disease, or in the opinion of the
        Investigator, would be unlikely to tolerate or derive clinical benefit from appropriate
        standard of care therapy.

          -  Cohorts 1 and 2: enrollment will be restricted to patients with evidence of a RET gene
             alteration in tumor.

          -  Cohorts 1 and 2: at least one measurable lesion as defined by RECIST 1.1 or RANO, as
             appropriate to tumor type and not previously irradiated.

          -  Cohorts 3 and 4: Enrollment closed.

          -  Cohort 5: (up to 200 patients):

               -  Cohorts 1 and 2 without measurable disease;

               -  MTC syndrome spectrum cancers (e.g., MTC, pheochromocytoma), cancers with
                  neuroendocrine features/differentiation, or poorly differentiated thyroid cancers
                  with other RET alteration/activation may be allowed with prior Sponsor approval;

               -  cfDNA positive for a RET gene alteration not known to be present in a tumor
                  sample.

          -  Cohort 6 (up to 50 patients):

               -  Patients who otherwise are eligible for Cohorts 1, 2 or 5 who discontinued
                  another RET inhibitor due to intolerance may be eligible with prior Sponsor
                  approval.

        Key Exclusion Criteria (Phase 1 and Phase 2):

          -  Phase 2 Cohorts 1 and 2: an additional known oncogenic driver.

          -  Cohorts 3 and 4: Enrollment closed.

          -  Cohorts 1, 2 and 5: prior treatment with a selective RET inhibitor

        Notes:

        Patients otherwise eligible for Cohorts 1, 2, and 5 who discontinued another selective RET
        inhibitor may be eligible for Phase 2 Cohort 6 with prior Sponsor approval.

        - Investigational agent or anticancer therapy (including chemotherapy, biologic therapy,
        immunotherapy, anticancer Chinese medicine or other anticancer herbal remedy) within 5
        half-lives or 2 weeks (whichever is shorter) prior to planned start of LOXO-292
        (selpercatinib). In addition, no concurrent investigational anti-cancer therapy is
        permitted.

        Note:

        Potential exception for this exclusion criterion will require a valid scientific
        justification and approval from the Sponsor.

          -  Major surgery (excluding placement of vascular access) within 4 weeks prior to planned
             start of LOXO-292 (selpercatinib).

          -  Radiotherapy with a limited field of radiation for palliation within 1 week of planned
             start of LOXO-292 (selpercatinib), with the exception of patients receiving radiation
             to more than 30% of the bone marrow or with a wide field of radiation, which must be
             completed at least 4 weeks prior to the first dose of study treatment.

          -  Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of
             starting study treatment with the exception of alopecia and Grade 2, prior
             platinum-therapy related neuropathy.

          -  Symptomatic primary CNS tumor, metastases, leptomeningeal carcinomatosis, or untreated
             spinal cord compression. Patients are eligible if neurological symptoms and CNS
             imaging are stable and steroid dose is stable for 14 days prior to the first dose of
             LOXO-292 (selpercatinib) and no CNS surgery or radiation has been performed for 28
             days, 14 days if stereotactic radiosurgery [SRS].

          -  Clinically significant active cardiovascular disease or history of myocardial
             infarction within 6 months prior to planned start of LOXO-292 (selpercatinib) or
             prolongation of the QT interval corrected (QTcF) &gt; 470 msec.

          -  Required treatment with certain strong CYP3A4 inhibitors or inducers and certain
             prohibited concomitant medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liz Olek, DO, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>855-RET-4-292 (855-738-4292)</phone>
    <email>clinicaltrials@loxooncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA) - Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Santa Clara, CA</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente- Vallejo</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine - Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics (START) Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University (NYU) Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina (UNC) - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (OHSU)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute, LLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Institute</name>
      <address>
        <city>Melbourne</city>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <zip>NSW 2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>VSZ 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Finsen Centre</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICM - Institut Regional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Wurzburg - Department of Internal Medicine I</name>
      <address>
        <city>Würzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital - Department of Clinical Oncology</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center - Dept. of Oncology</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Hebrew University Medical Center Ein Karem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel HaShomer</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori - National Cancer Institute</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Akashi</city>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa City</city>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5340021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Tottori</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital, Faculty of Medicine</name>
      <address>
        <city>Ōsaka-sayama</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz, START-Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid, Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Luzerner General Hospital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10002 R.O.C</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Surrey</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LOXO-292</keyword>
  <keyword>KIF5B-RET</keyword>
  <keyword>M918T</keyword>
  <keyword>CCDC6-RET</keyword>
  <keyword>RET-PTC1</keyword>
  <keyword>NCOA4-RET</keyword>
  <keyword>RET-PTC</keyword>
  <keyword>RET-PTC3</keyword>
  <keyword>RET-PTC4</keyword>
  <keyword>PRKAR1A-RET</keyword>
  <keyword>RET-PTC2</keyword>
  <keyword>GOLGA5-RET</keyword>
  <keyword>RET-PTC5</keyword>
  <keyword>ERC1-RET</keyword>
  <keyword>KTN1-RET</keyword>
  <keyword>RET-PTC8</keyword>
  <keyword>HOOK3-RET</keyword>
  <keyword>PCM1-RET</keyword>
  <keyword>TRIM24-RET</keyword>
  <keyword>RET-PTC6</keyword>
  <keyword>TRIM27-RET</keyword>
  <keyword>TRIM33-RET</keyword>
  <keyword>RET-PTC7</keyword>
  <keyword>AKAP13-RET</keyword>
  <keyword>FKBP15-RET</keyword>
  <keyword>SPECC1L-RET</keyword>
  <keyword>TBL1XR1-RET</keyword>
  <keyword>BCR-RET</keyword>
  <keyword>FGRF1OP-RET</keyword>
  <keyword>RFG8-RET</keyword>
  <keyword>RET-PTC9</keyword>
  <keyword>ACBD5-RET</keyword>
  <keyword>MYH13-RET</keyword>
  <keyword>CUX1-RET</keyword>
  <keyword>KIAA1468-RET</keyword>
  <keyword>FRMD4A-RET</keyword>
  <keyword>SQSTM1-RET</keyword>
  <keyword>AFAP1L2-RET</keyword>
  <keyword>PPFIBP2-RET</keyword>
  <keyword>EML4-RET</keyword>
  <keyword>PARD3-RET</keyword>
  <keyword>G533C</keyword>
  <keyword>C609F</keyword>
  <keyword>C609G</keyword>
  <keyword>C609R</keyword>
  <keyword>C609S</keyword>
  <keyword>C609Y</keyword>
  <keyword>C611F</keyword>
  <keyword>C611G</keyword>
  <keyword>C611S</keyword>
  <keyword>C611Y</keyword>
  <keyword>C611W</keyword>
  <keyword>C618F</keyword>
  <keyword>C618R</keyword>
  <keyword>C618S</keyword>
  <keyword>C620F</keyword>
  <keyword>C620R</keyword>
  <keyword>C620S</keyword>
  <keyword>C630R</keyword>
  <keyword>C630Y</keyword>
  <keyword>D631Y</keyword>
  <keyword>C634F</keyword>
  <keyword>C634G</keyword>
  <keyword>C634R</keyword>
  <keyword>C634S</keyword>
  <keyword>C634W</keyword>
  <keyword>C634Y</keyword>
  <keyword>K666E</keyword>
  <keyword>E768D</keyword>
  <keyword>L790F</keyword>
  <keyword>V804L</keyword>
  <keyword>V804M</keyword>
  <keyword>A883F</keyword>
  <keyword>S891A</keyword>
  <keyword>R912P</keyword>
  <keyword>CLIP1-RET</keyword>
  <keyword>Y806C</keyword>
  <keyword>RET fusion</keyword>
  <keyword>RET alteration</keyword>
  <keyword>RET mutation</keyword>
  <keyword>RET rearrangement</keyword>
  <keyword>RET translocation</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Cancer of Lung</keyword>
  <keyword>Cancer of the Lung</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Neoplasms, Lung</keyword>
  <keyword>Neoplasms, Pulmonary</keyword>
  <keyword>Pulmonary Cancer</keyword>
  <keyword>Pulmonary Neoplasms</keyword>
  <keyword>Respiratory Tract Neoplasms</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Carcinoma, Bronchogenic</keyword>
  <keyword>Bronchial Neoplasms</keyword>
  <keyword>Medullary Thyroid Cancer</keyword>
  <keyword>Papillary Thyroid Cancer</keyword>
  <keyword>Thyroid Diseases</keyword>
  <keyword>Thyroid Neoplasms</keyword>
  <keyword>Cancer of the Thyroid</keyword>
  <keyword>Cancer of Thyroid</keyword>
  <keyword>Neoplasms, Thyroid</keyword>
  <keyword>Thyroid Ademona</keyword>
  <keyword>Thyroid Cancer</keyword>
  <keyword>Thyroid Carcinoma</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Endocrine Gland Neoplasms</keyword>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Thoracic Neoplasms</keyword>
  <keyword>CNS tumor</keyword>
  <keyword>Primary CNS tumor</keyword>
  <keyword>Cancer of Colon</keyword>
  <keyword>Cancer of the Colon</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Colon Neoplasms</keyword>
  <keyword>Colonic Cancer</keyword>
  <keyword>Neoplasms, Colonic</keyword>
  <keyword>Malignant tumor of Breast</keyword>
  <keyword>Mammary Cancer</keyword>
  <keyword>Mammary Carcinoma, Human</keyword>
  <keyword>Mammary Neoplasm, Human</keyword>
  <keyword>Neoplasms, Breast</keyword>
  <keyword>Tumors, Breast</keyword>
  <keyword>Human Mammary Carcinoma</keyword>
  <keyword>Malignant Neoplasm of Breast</keyword>
  <keyword>Breast Carcinoma</keyword>
  <keyword>Breast Tumors</keyword>
  <keyword>Cancer of the Breast</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>RET Inhibitor</keyword>
  <keyword>MTC</keyword>
  <keyword>NSCLC</keyword>
  <keyword>selpercatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

